Interview Highlights
- Inpatients with severe depression with melancholic features respond better to mirtazapine, venlafaxine, and TCAs.
- Lurasidone is a suitable option for depression with mixed features, as well as for bipolar depression.
- TMS and esketamine have been approved by the FDA for depression. However, further investigation is needed, and, for now, these are at the end of the algorithm.
Text Version
This edition of Psychopharmacology Institute’s Expert Consultations features David Osser, M.D. Dr. Osser is an associate professor of psychiatry at Harvard Medical School. In this interview, we will discuss the algorithm for the treatment of unipolar depression.
Mohan Gautam, D.O.: I would like to begin our discussion by separating the major subcategories of depression. Which features are the most important for you
Unlock this Expert Consultation and earn 0.75 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.
Already have an account? Sign in
